Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
$512K Hold
3,043
0.02% 287
2023
Q3
$436K Hold
3,043
0.02% 288
2023
Q2
$560K Hold
3,043
0.02% 261
2023
Q1
$484K Sell
3,043
-55
-2% -$8.45K 0.02% 266
2022
Q4
$421K Buy
3,098
+55
+2% +$7.7K 0.02% 277
2022
Q3
$352K Hold
3,043
0.02% 284
2022
Q2
$369K Sell
3,043
-60
-2% -$7.55K 0.02% 281
2022
Q1
$442K Hold
3,103
0.02% 260
2021
Q4
$547K Hold
3,103
0.02% 239
2021
Q3
$479K Buy
3,103
+60
+2% +$8.72K 0.02% 253
2021
Q2
$410K Hold
3,043
0.02% 270
2021
Q1
$401K Hold
3,043
0.02% 250
2020
Q4
$360K Sell
3,043
-968
-24% -$113K 0.02% 227
2020
Q3
$423K Hold
4,011
0.03% 167
2020
Q2
$428K Hold
4,011
0.04% 162
2020
Q1
$320K Hold
4,011
0.03% 166
2019
Q4
$355K Hold
4,011
0.03% 182
2019
Q3
$328K Sell
4,011
-500
-11% -$40.6K 0.03% 176
2019
Q2
$425K Sell
4,511
-97
-2% -$8.28K 0.04% 156
2019
Q1
$390K Hold
4,608
0.04% 165
2018
Q4
$290K Sell
4,608
-223
-5% -$14.4K 0.03% 180
2018
Q3
$330K Hold
4,831
0.04% 177
2018
Q2
$301K Sell
4,831
-142
-3% -$8.68K 0.03% 187
2018
Q1
$259K Hold
4,973
0.03% 197
2017
Q4
$249K Hold
4,973
0.03% 191
2017
Q3
$217K Buy
+4,973
New +$193K 0.03% 222

Other funds holding NOVT

GW & Wade's NOVT Position: Q4 2023 in Review

GW & Wade held its Novanta (NOVT) position steady in Q4 2023 at 3,043 shares worth $512K. The position accounts for 0.02% of the portfolio, ranked #287.

GW & Wade first reported a position in NOVT in Q3 2017 and has held it in 26 quarters since. The position peaked at $560K in Q2 2023. 257 funds tracked by Wall St. Rank hold NOVT as of Q4 2023.

  • GW & Wade held 3,043 shares of Novanta worth $512K as of Q4 2023.
  • GW & Wade left its Novanta share count unchanged in Q4 2023.
  • Novanta made up 0.02% of GW & Wade's portfolio in Q4 2023, its #287 holding.
  • GW & Wade first reported a position in Novanta in Q3 2017 and has held it in 26 quarters since.
  • GW & Wade's Novanta position peaked at $560K in Q2 2023.
  • 257 funds tracked by Wall St. Rank held Novanta as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.